Financial_NNP Statements_NNP 87_CD ACCOUNTING_NNP POLICIES_NNPS BASIS_NNPS OF_IN ACCOUNTING_NNP basis_NN over_IN their_PRP$ useful_JJ economic_JJ lives_NNS from_IN Payments_NNS to_TO defined_VBN contribution_NN schemes_NNS The_DT consolidated_JJ financial_JJ statements_NNS have_VBP product_NN launch_NN ._.
Payments_NNS to_TO in-licence_NN are_VBP recognized_VBN in_IN the_DT income_NN statement_NN as_IN been_VBN prepared_VBN under_IN the_DT historical_JJ cost_NN products_NNS and_CC compounds_NNS from_IN external_JJ third_JJ they_PRP fall_VBP due_JJ ._.
convention_NN ,_, modified_VBN to_TO include_VB revaluation_NN parties_NNS ,_, generally_RB taking_VBG the_DT form_NN of_IN up-front_JJ to_TO fair_JJ value_NN of_IN certain_JJ financial_JJ instruments_NNS payments_NNS and_CC milestones_NNS ,_, are_VBP capitalized_VBN and_CC Taxation_NNP as_IN described_VBN below_IN ,_, in_IN accordance_NN with_IN the_DT amortised_JJ ,_, generally_RB on_IN a_DT straight_JJ line_NN basis_NN ,_, The_DT charge_NN for_IN taxation_NN is_VBZ based_VBN on_IN the_DT profits_NNS Companies_NNS Act_NNP 1985_CD and_CC International_NNP over_IN their_PRP$ economic_JJ lives_NNS from_IN launch_NN ._.
Under_IN for_IN the_DT year_NN and_CC takes_VBZ into_IN account_NN taxation_NN Financial_NNP Reporting_NNP Standards_NNP IFRSs_NNP as_IN this_DT policy_NN ,_, it_PRP is_VBZ not_RB possible_JJ to_TO determine_VB deferred_VBN because_IN of_IN temporary_JJ differences_NNS adopted_VBN by_IN the_DT European_NNP Union_NNP in_IN response_NN precise_JJ economic_JJ lives_NNS for_IN individual_JJ classes_NNS between_IN the_DT treatment_NN of_IN certain_JJ items_NNS for_IN to_TO the_DT IAS_NNP regulation_NN EC_NNP 1606_CD 2002_CD ._.
of_IN intangible_JJ ._.
However_RB ,_, lives_VBZ range_NN from_IN three_CD taxation_NN and_CC for_IN accounting_NN purposes_NNS ._.
Full_JJ years_NNS to_TO twenty_CD years_NNS ._.
Intangible_JJ assets_NNS relating_VBG provision_NN is_VBZ made_VBN for_IN the_DT tax_NN effects_NNS of_IN these_DT Where_WRB there_EX are_VBP significant_JJ differences_NNS to_TO to_TO products_NNS in_IN development_NN both_DT internally_RB differences_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP recognized_VBN US_NNP GAAP_NNP these_DT have_VBP been_VBN described_VBN in_IN the_DT generated_VBN and_CC externally_RB acquired_VBN are_VBP subject_JJ to_TO the_DT extent_NN that_IN it_PRP is_VBZ probable_JJ that_IN taxable_JJ US_NNP GAAP_NNP section_NN on_IN pages_NNS 130_CD to_TO 136_CD ._.
to_TO impairment_NN testing_NN at_IN each_DT balance_NN sheet_NN profit_NN will_MD be_VB available_JJ against_IN which_WDT the_DT asset_NN date_NN ._.
All_DT intangible_JJ assets_NNS are_VBP tested_VBN for_IN can_MD be_VB utilised_VBN ._.
This_DT requires_VBZ judgements_NNS to_TO In_IN preparing_VBG their_PRP$ individual_JJ financial_JJ statements_NNS ,_, impairment_NN when_WRB there_EX are_VBP indications_NNS that_WDT be_VB made_VBN in_IN respect_NN of_IN the_DT forecast_NN of_IN future_JJ the_DT accounting_NN policies_NNS of_IN some_DT overseas_JJ the_DT carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ ._.
subsidiaries_NNS and_CC associated_VBN undertakings_NNS Any_DT impairment_NN losses_NNS are_VBP recognized_VBN do_VBP not_RB conform_VB with_IN IFRSs_NNS ._.
Therefore_RB ,_, where_WRB immediately_RB in_IN the_DT income_NN statement_NN ._.
No_DT deferred_JJ tax_NN asset_NN or_CC liability_NN is_VBZ recognized_VBN appropriate_JJ ,_, adjustments_NNS are_VBP made_VBN in_IN order_NN in_IN respect_NN of_IN temporary_JJ differences_NNS associated_VBN to_TO present_VB the_DT Group_NNP Financial_NNP Statements_NNP Business_NNP combinations_NNS and_CC goodwill_NN with_IN investments_NNS in_IN subsidiaries_NNS ,_, branches_NNS on_IN a_DT consistent_JJ basis_NN ._.
On_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, fair_JJ values_NNS are_VBP and_CC joint_JJ ventures_NNS where_WRB the_DT Group_NNP is_VBZ able_JJ attributed_VBN to_TO the_DT identifiable_JJ assets_NNS ,_, liabilities_NNS to_TO control_VB the_DT timing_NN of_IN reversal_NN of_IN the_DT AstraZenecas_NNP management_NN considers_VBZ the_DT and_CC contingent_JJ liabilities_NNS acquired_VBN ._.
Goodwill_NN temporary_JJ differences_NNS and_CC it_PRP is_VBZ probable_JJ that_IN following_VBG to_TO be_VB the_DT most_RBS important_JJ accounting_NN arises_VBZ where_WRB the_DT fair_JJ value_NN of_IN the_DT consideration_NN the_DT temporary_JJ differences_NNS will_MD not_RB reverse_VB in_IN policies_NNS in_IN the_DT context_NN of_IN the_DT Groups_NNS operations_NNS ._.
given_VBN for_IN a_DT business_NN exceeds_VBZ the_DT fair_JJ value_NN the_DT foreseeable_JJ future_NN ._.
of_IN such_JJ assets_NNS ,_, liabilities_NNS and_CC contingent_JJ In_IN applying_VBG these_DT accounting_NN policies_NNS liabilities_NNS acquired_VBN ._.
Accruals_NNS for_IN tax_NN contingencies_NNS require_VBP management_NN makes_VBZ certain_JJ judgements_NNS and_CC management_NN to_TO make_VB judgements_NNS and_CC estimations_NNS ._.
Judgements_NNP include_VBP classification_NN Goodwill_NNP arising_VBG on_IN acquisitions_NNS is_VBZ capitalized_VBN estimates_NNS of_IN ultimate_JJ exposures_NNS in_IN relation_NN to_TO of_IN transactions_NNS between_IN the_DT income_NN statement_NN and_CC subject_NN to_TO an_DT impairment_NN review_NN ,_, both_DT tax_NN audit_NN issues_NNS ._.
Tax_NNP benefits_NNS are_VBP not_RB recognized_VBN and_CC balance_NN sheet_NN ,_, whilst_NN estimations_NNS focus_VB on_IN annually_RB and_CC when_WRB there_EX is_VBZ an_DT indication_NN that_WDT unless_IN the_DT tax_NN positions_NNS will_MD probably_RB be_VB areas_NNS such_JJ as_IN carrying_VBG values_NNS and_CC estimated_VBN lives_NNS ._.
the_DT carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ ._.
Once_RB considered_VBN to_TO be_VB probable_JJ ,_, Prior_RB to_TO 1_CD January_NNP 2003_CD ,_, goodwill_NN was_VBD management_NN reviews_NNS each_DT material_NN tax_NN benefit_NN The_DT accounting_NN policy_NN descriptions_NNS set_VBN out_RP the_DT amortised_VBN over_IN its_PRP$ estimated_VBN useful_JJ life_NN :_: such_JJ to_TO assess_VB whether_IN a_DT provision_NN should_MD be_VB areas_NNS where_WRB judgement_NN needs_VBZ exercising_VBG ,_, the_DT amortisation_NN ceased_VBD on_IN 31_CD December_NNP 2002_CD ._.
taken_VBN against_IN full_JJ recognition_NN of_IN that_DT benefit_NN most_RBS significant_JJ of_IN which_WDT are_VBP the_DT classification_NN of_IN on_IN the_DT basis_NN of_IN potential_JJ settlement_NN through_IN financial_JJ instruments_NNS and_CC the_DT transition_NN elections_NNS The_DT Groups_NNS policy_NN up_IN to_TO and_CC including_VBG 1997_CD negotiation_NN and_CC or_CC litigation_NN ._.
Any_DT recorded_VBN made_VBN under_IN IFRS_NNP 1_CD First-time_JJ Adoption_NN of_IN was_VBD to_TO eliminate_VB goodwill_NN arising_VBG upon_IN exposure_NN to_TO interest_NN on_IN tax_NN liabilities_NNS is_VBZ International_NNP Financial_NNP Reporting_NNP Standards_NNPS ._.
Under_IN IFRS_NNP 1_CD provided_VBN for_IN in_IN the_DT tax_NN charge_NN ._.
First-time_JJ Adoption_NN of_IN International_NNP Financial_NNP Revenue_NNP Reporting_NNP Standards_NNPS and_CC IFRS_NNPS 3_NNP Business_NNP Share-based_JJ payments_NNS Sales_NNS exclude_VBP inter-company_JJ sales_NNS and_CC valueCombinations_NNS ,_, such_JJ goodwill_NN will_MD remain_VB The_DT fair_JJ value_NN of_IN employee_NN share_NN option_NN plans_VBZ added_JJ taxes_NNS and_CC represent_VBP net_JJ invoice_NN value_NN eliminated_VBN against_IN reserves_NNS ._.
is_VBZ generally_RB calculated_VBN using_VBG the_DT Black-Scholes_NNP less_JJR estimated_JJ rebates_NNS ,_, returns_NNS and_CC settlement_NN model_NN ._.
In_IN accordance_NN with_IN IFRS_NNP 2_CD Share-based_JJ discounts_NNS ._.
Sales_NNS are_VBP recognized_VBN when_WRB the_DT Employee_NN benefits_NNS Payments_NNS ,_, the_DT resulting_VBG cost_NN is_VBZ recognized_VBN in_IN significant_JJ risks_NNS and_CC rewards_NNS of_IN ownership_NN have_VBP The_DT Group_NNP accounts_NNS for_IN pensions_NNS and_CC other_JJ the_DT income_NN statement_NN over_IN the_DT vesting_JJ period_NN been_VBN transferred_VBN to_TO a_DT third_JJ party_NN ._.
No_DT revenue_NN employee_NN benefits_NNS principally_RB healthcare_NN under_IN of_IN the_DT options_NNS ,_, being_VBG the_DT period_NN in_IN which_WDT the_DT is_VBZ recognized_VBN when_WRB there_EX are_VBP significant_JJ IAS_NNP 19_CD Employee_NNP Benefits_NNPS ._.
In_IN respect_NN of_IN services_NNS are_VBP received_VBN ._.
The_DT value_NN of_IN the_DT charge_NN uncertainties_NNS regarding_VBG the_DT consideration_NN defined_VBN benefit_NN plans_NNS ,_, obligations_NNS are_VBP measured_VBN is_VBZ adjusted_VBN to_TO reflect_VB expected_VBN and_CC actual_JJ to_TO be_VB received_VBN or_CC the_DT costs_NNS associated_VBN with_IN at_IN discounted_JJ present_JJ value_NN whilst_NN plan_NN assets_NNS levels_NNS of_IN options_NNS vesting_NN ,_, except_IN where_WRB the_DT the_DT transaction_NN ._.
are_VBP measured_VBN at_IN fair_JJ value_NN ._.
The_DT operating_NN and_CC failure_NN to_TO vest_NN is_VBZ as_IN a_DT result_NN of_IN not_RB meeting_VBG financing_NN costs_NNS of_IN such_JJ plans_NNS are_VBP recognized_VBN a_DT market_NN condition_NN ._.
All_DT plans_NNS are_VBP classified_VBN Research_NNP and_CC development_NN separately_RB in_IN the_DT income_NN statement_NN :_: service_NN as_IN equity_NN settled_VBN ._.
Research_NNP expenditure_NN is_VBZ recognized_VBN in_IN costs_NNS are_VBP spread_VBN systematically_RB over_IN the_DT lives_NNS the_DT income_NN statement_NN in_IN the_DT year_NN in_IN which_WDT of_IN employees_NNS and_CC financing_NN costs_NNS are_VBP Property_NN ,_, plant_NN and_CC equipment_NN it_PRP is_VBZ incurred_VBN ._.
recognized_VBN in_IN full_JJ in_IN the_DT periods_NNS in_IN which_WDT they_PRP The_DT Groups_NNS policy_NN is_VBZ to_TO write_VB off_RP the_DT difference_NN arise_VB ._.
Actuarial_JJ gains_NNS and_CC losses_NNS are_VBP recognized_VBN between_IN the_DT cost_NN of_IN each_DT item_NN of_IN property_NN ,_, Internal_NNP development_NN expenditure_NN is_VBZ recognized_VBN immediately_RB in_IN the_DT statement_NN of_IN recognized_VBN plant_NN and_CC equipment_NN and_CC its_PRP$ residual_JJ value_NN in_IN the_DT income_NN statement_NN in_IN the_DT year_NN in_IN which_WDT income_NN and_CC expense_NN ._.
systematically_RB over_IN its_PRP$ estimated_VBN useful_JJ life_NN ._.
it_PRP is_VBZ incurred_VBN unless_IN it_PRP meets_VBZ the_DT recognition_NN Assets_NNS under_IN construction_NN are_VBP not_RB depreciated_VBN ._.
criteria_NNS of_IN IAS_NNP 38_CD Intangible_NNP Assets_NNPS ._.
Regulatory_NNP Where_WRB the_DT calculation_NN results_NNS in_IN a_DT benefit_NN to_TO the_DT and_CC other_JJ uncertainties_NNS generally_RB mean_VBP that_IN Group_NNP ,_, the_DT recognized_VBN asset_NN is_VBZ limited_VBN to_TO the_DT Reviews_NNPS are_VBP made_VBN annually_RB of_IN the_DT estimated_VBN such_JJ criteria_NNS are_VBP not_RB met_VBN ._.
Where_WRB ,_, however_RB ,_, the_DT present_JJ value_NN of_IN any_DT future_JJ refunds_NNS from_IN the_DT remaining_VBG lives_NNS and_CC residual_JJ values_NNS of_IN individual_JJ recognition_NN criteria_NNS are_VBP met_VBN ,_, intangible_JJ assets_NNS plan_VBP or_CC reductions_NNS in_IN future_JJ contributions_NNS to_TO the_DT productive_JJ assets_NNS ,_, taking_VBG account_NN of_IN are_VBP capitalized_VBN and_CC amortised_VBN on_IN a_DT straight-line_JJ plan_NN ._.
commercial_JJ and_CC technological_JJ obsolescence_NN AstraZeneca_NNP Annual_JJ Report_NNP and_CC 88_CD Form_NN 20-F_JJ Information_NN 2005_CD ACCOUNTING_NNP POLICIES_NNPS CONTINUED_VBD as_RB well_RB as_IN normal_JJ wear_NN and_CC tear_VB ._.
Under_IN this_DT Inventories_NNS For_IN assets_NNS and_CC long_JJ term_NN loans_NNS classified_VBN policy_NN it_PRP becomes_VBZ impractical_JJ to_TO calculate_VB Inventories_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN or_CC as_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN and_CC assets_NNS average_JJ asset_NN lives_VBZ exactly_RB ._.
However_RB ,_, the_DT total_JJ net_JJ realisable_JJ value_NN ._.
The_DT first_JJ in_IN ,_, first_RB out_IN or_CC held_VBN for_IN trading_NN ,_, all_DT changes_NNS in_IN fair_JJ value_NN are_VBP lives_NNS range_VBP from_IN approximately_RB thirteen_VBN to_TO fifty_VB an_DT average_JJ method_NN of_IN valuation_NN is_VBZ used_VBN ._.
For_IN recognized_VBN in_IN the_DT income_NN statement_NN ._.
years_NNS for_IN buildings_NNS ,_, and_CC three_CD to_TO fifteen_CD years_NNS finished_VBN goods_NNS and_CC work_NN in_IN progress_NN ,_, cost_NN for_IN plant_NN and_CC equipment_NN ._.
All_DT items_NNS of_IN property_NN ,_, includes_VBZ directly_RB attributable_JJ costs_NNS and_CC certain_JJ Contingent_JJ liabilities_NNS plant_NN and_CC equipment_NN are_VBP tested_VBN for_IN impairment_NN overhead_NN expenses_NNS including_VBG depreciation_NN ._.
Through_IN the_DT normal_JJ course_NN of_IN business_NN ,_, when_WRB there_EX are_VBP indications_NNS that_IN the_DT carrying_VBG Selling_VBG expenses_NNS and_CC certain_JJ other_JJ overhead_JJ AstraZeneca_NNP is_VBZ involved_VBN in_IN legal_JJ disputes_NNS ,_, the_DT value_NN may_MD not_RB be_VB recoverable_JJ ._.
Any_DT impairment_NN expenses_NNS principally_RB central_JJ administration_NN settlement_NN of_IN which_WDT may_MD involve_VB cost_NN to_TO the_DT losses_NNS are_VBP written_VBN off_RP immediately_RB to_TO income_NN ._.
Net_JJ realisable_JJ value_NN is_VBZ Group_NNP ._.
Provision_NNP is_VBZ made_VBN where_WRB an_DT adverse_JJ determined_VBN as_IN estimated_VBN selling_NN price_NN less_RBR all_DT outcome_NN is_VBZ probable_JJ and_CC associated_VBN costs_NNS Borrowing_VBG costs_NNS estimated_VBN costs_NNS of_IN completion_NN and_CC costs_NNS to_TO be_VB can_MD be_VB estimated_VBN reliably_RB ._.
Borrowing_NN costs_NNS are_VBP recognized_VBN in_IN the_DT income_NN incurred_VBN in_IN marketing_NN ,_, selling_VBG and_CC distribution_NN ._.
AstraZeneca_NNP is_VBZ exposed_VBN to_TO environmental_JJ Write_JJ downs_NNS of_IN inventory_NN occur_VBP regularly_RB in_IN the_DT liabilities_NNS relating_VBG to_TO its_PRP$ past_JJ operations_NNS ,_, Leases_VBZ general_JJ course_NN of_IN business_NN and_CC are_VBP included_VBN principally_RB in_IN respect_NN of_IN soil_NN and_CC groundwater_NN Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP capitalized_VBN in_IN cost_NN of_IN sales_NNS in_IN the_DT income_NN statement_NN ._.
Provisions_NNS for_IN these_DT costs_NNS and_CC included_VBN in_IN tangible_JJ fixed_JJ assets_NNS at_IN fair_JJ are_VBP made_VBN when_WRB there_EX is_VBZ a_DT present_JJ obligation_NN value_NN ._.
Each_DT asset_NN is_VBZ depreciated_VBN over_IN the_DT Financial_NNP instruments_NNS and_CC where_WRB it_PRP is_VBZ probable_JJ that_IN expenditure_NN shorter_JJR of_IN the_DT lease_NN term_NN or_CC its_PRP$ useful_JJ life_NN ._.
Financial_NNP instruments_NNS are_VBP recorded_VBN initially_RB at_IN on_IN remedial_JJ work_NN will_MD be_VB required_VBN and_CC that_IN The_DT obligations_NNS related_VBN to_TO finance_VB leases_NNS ,_, net_JJ fair_JJ value_NN ._.
Subsequent_JJ measurement_NN depends_VBZ a_DT reliable_JJ estimate_NN can_MD be_VB made_VBN of_IN the_DT cost_NN ._.
of_IN finance_NN charges_NNS in_IN respect_NN of_IN future_JJ periods_NNS ,_, on_IN the_DT designation_NN of_IN the_DT instrument_NN ,_, as_IN follows_VBZ :_: Provisions_NNS are_VBP discounted_VBN where_WRB the_DT effect_NN are_VBP included_VBN ,_, as_IN appropriate_JJ ,_, under_IN current_JJ is_VBZ material_NN ._.
Investments_NNP other_JJ than_IN interests_NNS in_IN joint_JJ ventures_NNS ,_, associates_NNS and_CC fixed_VBN deposits_NNS Foreign_JJ currencies_NNS The_DT interest_NN element_NN of_IN the_DT rental_JJ obligation_NN and_CC short_JJ term_NN investments_NNS other_JJ than_IN Income_NNP statement_NN items_NNS in_IN foreign_JJ currencies_NNS is_VBZ allocated_VBN to_TO accounting_NN periods_NNS during_IN the_DT fixed_VBN deposits_NNS are_VBP normally_RB designated_VBN are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN average_JJ lease_NN term_NN to_TO reflect_VB a_DT constant_JJ rate_NN of_IN interest_NN as_IN available_JJ for_IN sale_NN ._.
Where_WRB the_DT exposure_NN exchange_NN rates_NNS ,_, which_WDT approximate_JJ to_TO actual_JJ on_IN the_DT remaining_VBG balance_NN of_IN the_DT obligation_NN for_IN to_TO a_DT change_NN in_IN fair_JJ value_NN of_IN such_PDT an_DT asset_NN rates_NNS ,_, for_IN the_DT relevant_JJ accounting_NN periods_NNS ._.
is_VBZ substantially_RB offset_VBN by_IN the_DT exposure_NN Assets_NNS and_CC liabilities_NNS are_VBP translated_VBN at_IN exchange_NN to_TO a_DT change_NN in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS ,_, rates_NNS prevailing_VBG at_IN the_DT date_NN of_IN the_DT Group_NNP Rentals_NNPS under_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO the_DT asset_NN is_VBZ generally_RB classified_VBN as_IN fair_JJ value_NN balance_NN sheet_NN ._.
the_DT income_NN statement_NN on_IN a_DT straight-line_JJ basis_NN ._.
Exchange_NNP gains_NNS and_CC losses_NNS on_IN short_JJ term_NN Subsidiaries_NNS ,_, associates_NNS and_CC joint_JJ ventures_NNS Fixed_VBN deposits_NNS ,_, comprising_VBG principally_RB foreign_JJ currency_NN borrowings_NNS and_CC deposits_NNS are_VBP A_DT subsidiary_NN is_VBZ an_DT entity_NN controlled_VBN ,_, directly_RB or_CC funds_NNS held_VBN with_IN banks_NNS and_CC other_JJ financial_JJ included_VBN within_IN finance_NN income_NN and_CC finance_NN indirectly_RB ,_, by_IN AstraZeneca_NNP ._.
Control_NNP is_VBZ regarded_VBN institutions_NNS ,_, classified_VBN as_IN loans_NNS and_CC expense_NN ._.
Exchange_NNP differences_NNS on_IN all_DT other_JJ as_IN the_DT power_NN to_TO govern_VB the_DT financial_JJ and_CC receivables_NN ,_, and_CC short_JJ term_NN borrowings_NNS transactions_NNS ,_, except_IN relevant_JJ foreign_JJ currency_NN operating_VBG policies_NNS of_IN the_DT entity_NN so_RB as_IN to_TO obtain_VB and_CC overdrafts_NNS ,_, classified_VBN as_IN other_JJ liabilities_NNS ,_, loans_NNS ,_, are_VBP taken_VBN to_TO operating_VBG profit_NN ._.
are_VBP held_VBN at_IN amortised_JJ cost_NN ._.
In_IN the_DT consolidated_JJ financial_JJ statements_NNS An_DT associate_NN is_VBZ an_DT undertaking_NN ,_, not_RB being_VBG Derivatives_NNS ,_, comprising_VBG interest_NN rate_NN swaps_NNS ,_, exchange_NN differences_NNS arising_VBG on_IN consolidation_NN a_DT subsidiary_NN or_CC joint_JJ venture_NN ,_, over_IN whose_WP$ foreign_JJ exchange_NN contracts_NNS and_CC options_NNS of_IN the_DT net_JJ investments_NNS in_IN subsidiaries_NNS ,_, joint_JJ commercial_JJ and_CC financial_JJ policy_NN decisions_NNS and_CC embedded_VBN derivatives_NNS ,_, are_VBP classified_JJ ventures_NNS and_CC associates_NNS together_RB with_IN those_DT AstraZeneca_NNP has_VBZ significant_JJ influence_NN ._.
on_IN relevant_JJ foreign_JJ currency_NN loans_NNS are_VBP taken_VBN directly_RB to_TO equity_NN via_IN the_DT statement_NN of_IN recognized_VBN A_DT joint_JJ venture_NN is_VBZ an_DT entity_NN which_WDT is_VBZ jointly_RB Long_JJ term_NN loans_NNS ,_, where_WRB the_DT change_NN in_IN fair_JJ income_NN and_CC expense_NN ._.
controlled_VBN by_IN AstraZeneca_NNP and_CC one_CD or_CC more_JJR value_NN is_VBZ substantially_RB offset_VBN by_IN the_DT exposure_NN other_JJ venturers_NNS under_IN a_DT contractual_JJ arrangement_NN ._.
to_TO a_DT change_NN in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS ,_, IFRS_NNP transitional_JJ arrangements_NNS are_VBP classified_VBN as_IN fair_JJ value_NN through_IN profit_NN or_CC and_CC early_JJ adoption_NN AstraZenecas_NNP share_NN of_IN the_DT profits_NNS less_RBR losses_NNS loss_NN when_WRB certain_JJ criteria_NNS are_VBP met_VBN ._.
When_WRB preparing_VBG the_DT consolidated_JJ balance_NN of_IN joint_JJ ventures_NNS and_CC associates_NNS is_VBZ included_VBN in_IN sheet_NN under_IN IFRS_NNP at_IN 1_CD January_NNP 2003_CD ,_, the_DT date_NN the_DT Group_NNP income_NN statement_NN on_IN the_DT equity_NN Changes_NNS in_IN the_DT fair_JJ value_NN of_IN financial_JJ of_IN transition_NN ,_, the_DT following_VBG optional_JJ exemptions_NNS accounting_VBG basis_NN ._.
The_DT holding_NN value_NN of_IN instruments_NNS are_VBP dealt_VBN with_IN as_IN follows_VBZ :_: from_IN full_JJ retrospective_JJ application_NN of_IN IFRS_NNP associates_NNS and_CC joint_JJ ventures_NNS in_IN the_DT Group_NNP accounting_NN policies_NNS have_VBP been_VBN adopted_VBN :_: balance_NN sheet_NN is_VBZ calculated_VBN by_IN reference_NN to_TO For_IN available_JJ for_IN sale_NN assets_NNS ,_, exchange_NN losses_NNS AstraZenecas_NNP equity_NN in_IN the_DT net_JJ assets_NNS of_IN such_JJ and_CC impairments_NNS are_VBP taken_VBN to_TO the_DT income_NN Business_NN combinations_NNS the_DT provisions_NNS associates_NNS and_CC joint_JJ ventures_NNS ,_, as_IN shown_VBN by_IN the_DT statement_NN ._.
All_DT other_JJ changes_NNS in_IN fair_JJ value_NN are_VBP of_IN IFRS_NNS 3_CD have_VBP been_VBN applied_VBN prospectively_RB most_RBS recent_JJ accounts_NNS available_JJ ,_, adjusted_JJ taken_VBN to_TO reserves_NNS ._.
On_IN disposal_NN of_IN the_DT related_VBN from_IN 1_CD January_NNP 2003_CD ._.
Business_NNP combinations_NNS where_WRB appropriate_JJ and_CC including_VBG goodwill_NN on_IN asset_NN ,_, the_DT accumulated_VBN changes_NNS in_IN fair_JJ value_NN that_WDT occurred_VBD before_IN 1_CD January_NNP 2003_CD have_VBP acquisitions_NNS made_VBD since_IN 1_CD January_NNP 1998_CD ._.
recorded_VBN in_IN reserves_NNS are_VBP included_VBN in_IN the_DT gain_NN not_RB been_VBN restated_VBN ._.
or_CC loss_NN recorded_VBN in_IN the_DT income_NN statement_NN ._.
Financial_NNP Statements_NNP 89_CD Employee_NN benefits_NNS the_DT accumulated_VBN actuarial_JJ gains_NNS and_CC losses_NNS in_IN respect_NN of_IN employee_NN defined_VBN benefit_NN plans_NNS have_VBP been_VBN recognized_VBN in_IN full_JJ through_IN reserves_NNS ._.
Cumulative_JJ exchange_NN differences_NNS cumulative_JJ translation_NN differences_NNS on_IN net_JJ investments_NNS have_VBP been_VBN set_VBN to_TO zero_VB at_IN 1_CD January_NNP 2003_CD ._.
The_DT following_VBG optional_JJ exemptions_NNS from_IN full_JJ retrospective_JJ application_NN of_IN IFRS_NNP accounting_NN policies_NNS have_VBP not_RB been_VBN adopted_VBN :_: Fair_NNP value_NN or_CC revaluation_NN an_DT entity_NN may_MD elect_VB to_TO use_VB fair_JJ value_NN or_CC a_DT previous_JJ GAAP_NNP revaluation_NN at_IN the_DT opening_NN balance_NN sheet_NN date_NN ._.
Compound_NN financial_JJ instruments_NNS if_IN the_DT compound_NN financial_JJ instruments_NNS are_VBP no_RB longer_RB outstanding_JJ at_IN the_DT date_NN of_IN transition_NN ,_, the_DT entity_NN is_VBZ not_RB required_VBN to_TO split_VB the_DT instrument_NN into_IN the_DT separate_JJ equity_NN and_CC liability_NN components_NNS ._.
In_IN addition_NN ,_, the_DT Group_NNP has_VBZ chosen_VBN to_TO restate_VB comparative_JJ information_NN with_IN respect_NN to_TO IAS_NNP 32_CD Financial_NNP Instruments_NNPS :_: Disclosure_NN and_CC Presentation_NN and_CC IAS_NNP 39_CD Financial_NNP Instruments_NNPS :_: Recognition_NN and_CC Measurement_NNP ._.
IFRS_NNS 2_CD Sharebased_JJ Payments_NNS has_VBZ been_VBN adopted_VBN with_IN full_JJ retrospective_JJ application_NN ._.
The_DT Group_NNP has_VBZ also_RB adopted_VBN the_DT amendment_NN to_TO IAS_NNP 19_CD Employee_NNP Benefits_NNPS early_RB ,_, allowing_VBG actuarial_JJ gains_NNS or_CC losses_NNS to_TO be_VB recognized_VBN directly_RB in_IN the_DT consolidated_JJ statement_NN of_IN income_NN and_CC expense_NN in_IN the_DT period_NN in_IN which_WDT they_PRP arise_VBP ._.
Comparative_JJ information_NN has_VBZ been_VBN prepared_VBN on_IN this_DT basis_NN ._.
Accounting_NN standards_NNS issued_VBN but_CC not_RB adopted_VBN IFRS_NNP 7_CD Financial_NNP Instruments_NNPS :_: Disclosures_NNS was_VBD issued_VBN in_IN August_NNP 2005_CD ._.
It_PRP revises_VBZ and_CC enhances_VBZ previous_JJ disclosures_NNS required_VBN by_IN IAS_NNP 32_CD and_CC IAS_NNP 30_CD Disclosures_NNS in_IN the_DT Financial_NNP Statements_NNP of_IN Banks_NNPS and_CC similar_JJ Financial_NNP Institutions_NNS ._.
It_PRP is_VBZ effective_JJ for_IN annual_JJ periods_NNS beginning_VBG on_IN or_CC after_IN 1_CD January_NNP 2007_CD ._.
The_DT adoption_NN of_IN IFRS_NNP 7_CD will_MD have_VB no_DT impact_NN upon_IN the_DT results_NNS or_CC net_JJ assets_NNS of_IN AstraZeneca_NNP ._.
Accounting_NNP policies_NNS in_IN respect_NN of_IN the_DT company_NN information_NN for_IN AstraZeneca_NNP PLC_NNP are_VBP set_VBN out_RP on_IN page_NN 141_CD ._.
These_DT are_VBP in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
